BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/26/2024 9:16:41 AM | Browse: 60 | Download: 395
 |
Received |
|
2024-08-10 06:22 |
|
Peer-Review Started |
|
2024-08-10 06:22 |
|
First Decision by Editorial Office Director |
|
2024-10-24 02:24 |
|
Return for Revision |
|
2024-10-24 02:24 |
|
Revised |
|
2024-11-01 22:37 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-11-18 02:44 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-11-19 10:29 |
|
Articles in Press |
|
2024-11-19 10:29 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-11-21 08:36 |
|
Publish the Manuscript Online |
|
2024-11-26 09:16 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Sodium-dependent glucose transporter 2 inhibitors: Transforming diabetic cardiomyopathy management
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Chun-Han Cheng, Wen-Rui Hao and Tzu-Hurng Cheng |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung 404328, Taiwan. thcheng@mail.cmu.edu.tw |
| Key Words |
Sodium-dependent glucose transporter 2 inhibitors; Diabetic cardiomyopathy; Asymptomatic heart failure; Cardiac function; Type 2 diabetes |
| Core Tip |
This article emphasizes the clinical importance of sodium-dependent glucose transporter 2 inhibitors (SGLT2is) in managing myocardial function for patients with type 2 diabetes and asymptomatic heart failure. By improving cardiac function, reducing oxidative stress, and lowering inflammation, SGLT2is present a promising therapeutic strategy. Early intervention with SGLT2is can prevent the progression of diabetic cardiomyopathy, highlighting their transformative potential in the treatment of asymptomatic heart failure in patients with diabetes. |
| Publish Date |
2024-11-26 09:16 |
| Citation |
Cheng CH, Hao WR, Cheng TH. Sodium-dependent glucose transporter 2 inhibitors: Transforming diabetic cardiomyopathy management. World J Cardiol 2024; 16(12): 781-786 |
| URL |
https://www.wjgnet.com/1949-8462/full/v16/i12/781.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v16.i12.781 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
